Abstract

Previous studies have revealed the antitumor potential of Poria cocos Wolf against a broad spectrum of cancers. However, the biological activity of P. cocos against lung cancer, which is known as the leading cause of cancer mortality worldwide, and its underlying chemical and molecular basis, remain to be investigated. We aimed to evaluate the in vitro cytotoxicity of P. cocos toward human lung adenocarcinoma cells with different p53 statuses, to identify the bioactive constituents of P. cocos, and explicate the molecular mechanisms underlying the cytotoxicity of these constituents in human lung adenocarcinoma cells. An EtOH extract of the sclerotia of P. cocos exhibited cytotoxicity toward four human lung cancer cell lines: A549, H1264, H1299, and Calu-6, regardless of their p53 status. Chemical investigation of the extract resulted in the isolation of two triterpenoids, dehydroeburicoic acid monoacetate (1) and acetyl eburicoic acid (4); a sterol, 9,11-dehydroergosterol peroxide (2); and a diterpenoid, dehydroabietic acid (3). All of the isolated compounds were cytotoxic to the lung adenocarcinoma cell lines, exhibiting IC50 values ranging from 63.6 μM to 171.0 μM at 48 h of treatment. The cytotoxicity of the extract and the isolated compounds were found to be mediated by apoptosis, and accompanied by elevated Bax expression and/or Bcl-2 phosphorylation along with caspase-3 activation. Our data demonstrate that the sclerotium of P. cocos and its four bioactive constituents (1–4) exert cytotoxicity against human lung adenocarcinoma cells, regardless of their p53 status, by inducing apoptosis associated with mitochondrial perturbation, and proposing the potential to employ P. cocos in the treatment of lung cancer.

Highlights

  • IntroductionDespite considerable advances in cancer diagnosis and management, the prognosis of lung cancer patients continues to be unsatisfactory, as the five-year survival rate is less than 16%

  • Lung cancer is known as the most prevalently diagnosed cancer worldwide [1]

  • In order to continue with our efforts to screen mushrooms that manifest anticancer potential against lung cancer and identify compounds that contribute to the activity [19,20,21], we evaluated the biological activity of an EtOH extract of the sclerotia of P. cocos in four human lung adenocarcinoma cell lines, A549, H1264, H1299, and Calu-6, accompanying different p53 status

Read more

Summary

Introduction

Despite considerable advances in cancer diagnosis and management, the prognosis of lung cancer patients continues to be unsatisfactory, as the five-year survival rate is less than 16%. Mushrooms, especially medicinal ones, have been demonstrated to be promising and productive natural sources of bioactive compounds with various pharmacological properties that are effective for cancer management, such as cytotoxicity against cancer cells, as well as antioxidant, anti-angiogenic, and immunomodulatory activities [3,4]. It is clinically significant to screen mushrooms with therapeutic potential for lung cancer intervention and elucidate the chemical and molecular basis for their anticancer activity. Protein-bound polysaccharide K (PSK) isolated from Coriolus versicolor was approved in Japan for its clinical use to treat patients with gastric, colorectal, and small-cell lung cancer [5]. Various fungal metabolites and their derivatives, including aphidicolin, fumagillin, and phenylahistin, are currently being evaluated for their anticancer efficacy in clinical trials [6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call